High-dose intravenous immunoglobulin pulse therapy in patients with progressive immunoglobulin A nephropathy: A long-term follow-up

Clinical and Experimental Immunology

Volumn 146, Issue 1, 2006, Pages 47-53

  Rasche, F M ^a   Keller, F ^a,c   Lepper, P M ^b   Aymanns, C ^d   Karges, W ^a   Sailer, L C ^a   Müller, L Von ^a   Czock, D ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF ULM   (Germany)

^d NONE

Author keywords

High dose immunoglobulin therapy; IgA nephropathy; Immunosuppression; Loss of renal function

Indexed keywords

CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN 7S;

ACUTE KIDNEY FAILURE; ADULT; ANAPHYLAXIS; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DEEP VEIN THROMBOSIS; DISEASE COURSE; DOSE RESPONSE; DRUG PULSE THERAPY; FOLLOW UP; GLOMERULUS FILTRATION; HEMODIALYSIS; HUMAN; HYPERKALEMIA; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FAILURE; KIDNEY FUNCTION; LONG TERM CARE; MALE; MYALGIA; PRIORITY JOURNAL; PROTEINURIA; SURVIVAL; TREATMENT OUTCOME;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, IGA; HUMANS; IMMUNIZATION, PASSIVE; LINEAR MODELS; MALE; MIDDLE AGED; PROTEINURIA; TREATMENT OUTCOME;

EID: 33748682406     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2006.03189.x     Document Type: Article

References (28)

1. Barratt J, Feehally J. IgA nephropathy. J Am Soc Nephrol 2005; 16:2088-97.
2. Floege J, Feehally J. IgA nephropathy: recent developments. J Am Soc Nephrol 2000; 11:2395-403.
3. D'Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis 2000; 36:227-37.
4. Rasche FM, Schwarz A, Keller F. Tonsillectomy does not prevent a progressive course in IgA nephropathy. Clin Nephrol 1999; 51:147-52.
5. Hiki Y, Odani H, Takahashi M et al. Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int 2001; 59:1077-85.
6. Moura IC, Arcos-Fajardo M, Sadaka C et al. Glycosylation and size of IgA1 are essential for interaction with mesangial transferrin receptor in IgA nephropathy. J Am Soc Nephrol 2004; 15:622-34.
7. Novak J, Vu HL, Novak L, Julian BA, Mestecky J, Tomana M. Interactions of human mesangial cells with IgA and IgA-containing immune complexes. Kidney Int 2002; 62:465-75.
8. Pozzi C, Andrulli S, Del Vecchio L et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 2004; 15:157-63.
9. Ballardie FW. IgA nephropathy treatment 25 years on: can we halt progression? The evidence base. Nephrol Dial Transplant 2004; 19:1041-6.
10. Rasche FM, Klotz CH, Czock D et al. Cyclophosphamide pulse therapy in advanced progressive IgA nephropathy. Nephron Clin Pract 2003; 93:131-6.
11. Floege J, Eitner F. Present and future therapy options in IgA-nephropathy. J Nephrol 2005; 18:354-61.
12. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345:747-55.
13. Rostoker G, Desvaux-Belghiti D, Pilatte Y et al. High-dose immunoglobulin therapy for severe IgA nephropathy and Henoch-Schonlein purpura. Ann Intern Med 1994; 120:476-84.
14. Haas M. Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. Am J Kidney Dis 1997; 29:829-42.
15. Lee HS, Lee MS, Lee SM et al. Histological grading of IgA nephropathy predicting renal outcome: revisiting H. S. Lee's glomerular grading system. Nephrol Dial Transplant 2005; 20:342-8.
16. Poggio ED, Wang X, Greene T, Van Lente F, Hall PM. Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol 2004; 22:22.
17. Hansen-Schmidt S, Silomon J, Keller F. Osmotic nephrosis due to high-dose immunoglobulin therapy containing sucrose (but not with glycine) in a patient with immunoglobulin A nephritis. Am J Kidney Dis 1996; 28:451-3.
18. Chapman SA, Gilkerson KL, Davin TD, Pritzker MR. Acute renal failure and intravenous immune globulin: occurs with sucrose-stabilized, but not with D-sorbitol-stabilized, formulation. Ann Pharmacother 2004; 38:2059-67.
19. Feehally J. Treating IgA nephropathy - who, when and how? Nephron Clin Pract 2003; 93:C47-8.
20. Floege J. Evidence-based recommendations for immunosuppression in IgA nephropathy: handle with caution. Nephrol Dial Transplant 2003; 18:241-5.
21. Praga M, Gutierrez E, Gonzalez E, Morales E, Hernandez E. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol 2003; 14:1578-83.
22. Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 2002; 13:142-8.
23. Pozzi C, Bolasco PG, Fogazzi GB et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 1999; 353:883-7.
24. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999; 340:227-8.
25. Rostoker G, Rymer JC, Bagnard G, Petit-Phar M, Griuncelli M, Pilatte Y. Imbalances in serum proinflammatory cytokines and their soluble receptors: a putative role in the progression of idiopathic IgA nephropathy (IgAN) and Henoch-Schonlein purpura nephritis, and a potential target of immunoglobulin therapy? Clin Exp Immunol 1998; 114:468-76.
26. Maschio G, Cagnoli L, Claroni F et al. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomized, placebo-controlled study. Nephrol Dial Transplant 1994; 9:265-9.
27. Dal Canton A, Amore A, Barbano G et al. One-year angiotensin-converting enzyme inhibition plus mycophenolate mofetil immunosuppression in the course of early IgA nephropathy: a multicenter, randomised, controlled study. J Nephrol 2005; 18:136-40.
28. Hogg RJ, Wyatt RJ. A randomized controlled trial of mycophenolate mofetil in patients with IgA nephropathy [ISRCTN62557616]. BMC Nephrol 2004; 5:3.